Sanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated April 28, 2026, titled "Sanofi Consumer Healthcare India Limited reports Q1 26 Revenue at ₹2,292 MN, Net Profit at ₹678 MN".
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanofi Consumer Healthcare India Limited reported strong Q1 2026 results for the quarter ending March 31, 2026. Revenue stood at ₹2,292 million, up 33% year-on-year, driven by 15.5% growth in domestic sales (aided by relaunches of previously recalled products) and a 144% surge in export sales from a low base. Profit After Tax came in at ₹678 million, growing 36% YoY. The company operates independently following its demerger from Sanofi India Limited on June 1, 2024, focusing on consumer healthcare segments including allergy, digestive wellness, pain care, and multivitamins.
Both revenue and profit grew at robust rates above 30%, indicating strong operational performance. The double-digit domestic sales growth and sharp export recovery signal healthy business momentum, which is likely positive for the stock.